Safety, Tolerability, and Pharmacokinetics of Lumateperone Long-Acting Injectable Formulations in Patients With Schizophrenia or Schizoaffective Disorder

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2024
Study ITI-007-037 is a Phase 1b, open-label study to evaluate the safety, tolerability, and PK of lumateperone long-acting injectable (LAI) formulations after a single intramuscular injection in patients with stale schizophrenia or schizoaffective disorder.
Epistemonikos ID: 2adbf4082b000b01ab78aef500c368b8fcc19823
First added on: Apr 17, 2025